Johnson & Johnson Gains Momentum from Dual Growth Engines

Johnson & Johnson is demonstrating robust performance across its two primary business segments. The company’s oncology franchise is being powered by its CAR-T cell therapy, Carvykti, which is experiencing remarkable revenue expansion. Simultaneously, its medical devices division received a significant boost from compelling new long-term data for the Impella CP heart pump. Alongside these successes, the healthcare giant is also making strategic decisions to refine its development pipeline.

Oncology Drug Delivers Explosive Growth

A standout performer in the second quarter of 2025 was the cell therapy Carvykti (ciltacabtagene autoleucel), which became a major growth driver for J&J. Sales skyrocketed to $439 million, representing a staggering 136 percent increase compared to the same period last year. This performance puts the therapy on an annualized revenue run rate of approximately $1.7 billion. This surge follows an expanded FDA approval for earlier use in treating multiple myeloma and the presentation of convincing five-year survival data from the pivotal CARTITUDE-1 clinical trial. The strong performance of Carvykti contributed to the overall Innovative Medicine segment growing by 5.8 percent.

• Q2 Revenue: $439 million (+136% YoY)
• Annualized Run Rate: $1.7 billion

Medical Device Strengthened by Clinical Data

In the MedTech segment, Johnson & Johnson’s Impella CP heart pump delivered what can be described as practice-changing data. A decade-long study demonstrated that the device reduced mortality by 16.3 percent in STEMI patients. This evidence of superior long-term efficacy prompted the American College of Cardiology (ACC) and the American Heart Association (AHA) to upgrade their treatment guidelines for the device to a Class 2a recommendation. This endorsement significantly bolsters the product’s competitive standing within the high-growth cardiac pump market.

Should investors sell immediately? Or is it worth buying Johnson & Johnson?

Strategic Pipeline Pruning Underway

Despite these positive developments, Johnson & Johnson is maintaining a disciplined approach to its R&D investments. The company has decided to discontinue the development of nipocalimab for rheumatoid arthritis. This decision came after the drug, used in combination with an anti-TNFα therapy, yielded disappointing results in a Phase IIa study. However, management continues to believe the antibody holds blockbuster potential, affirming its overall revenue potential exceeds $5 billion across other disease indications.

Strong Fundamentals Outweigh Market Volatility

These recent positive updates build upon a foundation of strong second-quarter earnings for fiscal year 2025. Johnson & Johnson reported earnings per share (EPS) of $2.77 on revenue of $23.74 billion, exceeding market expectations. The company’s confidence is further illustrated by its decision to raise its full-year 2025 financial guidance. Additionally, shareholders are set to receive a quarterly dividend payment of $1.30 per share on September 9.

The critical question for investors is whether this powerful fundamental momentum can provide a lasting lift to the company’s share price. The next quarterly report, scheduled for release around October 21, 2025, may provide the next major catalyst.